Specifically, we show that responsiveness to alternative HER-targeted inhibitors, such as gefitinib and cetuximab, is dramatically potentiated by long-term trastuzumab treatment of ovarian cancer cells. ❋ Jason Wilken (2010)
The drug, known as trastuzumab-DM1, or T-DM1, is the first conjugated monoclonal antibody to be reviewed by the FDA and has realistic chances to be approved in some breast cancer patients by the regulator given the medicine's strong trial results, analysts said. ❋ Unknown (2010)
Treatment with a drug called trastuzumab Herceptin can block the growth signals transmitted by the gene, slowing the progress of the cancer and making it more susceptible to chemotherapy, Russell said. ❋ Unknown (2011)
Roche is using Halozyme's human hyaluronidase to develop an injectible form of trastuzumab, which is currently available only as an intravenous drug that takes about an hour to administer, often in a hospital. ❋ Unknown (2010)
The use of intact antibodies as the basis for radiotracer development, such as trastuzumab which is used routinely in the clinic worldwide, also has the advantage of expediting preclinical and clinical translation. ❋ Jason P. Holland Et Al. (2010)
Genentech unit has filed an application with the Food and Drug Administration for a novel cancer drug, known as trastuzumab-DM1, the company said Wednesday. ❋ Unknown (2010)
The drug, called trastuzumab-DM1, or T-DM1 for short, is designed to help women with advanced HER2-positive breast cancer who have previously received multiple HER2-targeted medicines and chemotherapies, including Genentech's Herceptin. ❋ Unknown (2010)
T-DM1 is composed of the breast cancer drug trastuzumab, which is marketed as Herceptin by ❋ Unknown (2010)
Herceptin, also known as trastuzumab, was approved for use in 1998 for women whose advanced breast cancer expresses Human Epidermal growth factor Receptor 2, or HER2.
The study found that patients who used Herceptin (also known by the generic name trastuzumab) and chemotherapy together were 25 percent less likely to experience a cancer recurrence or death than those who used the drug after chemotherapy. ❋ Unknown (2009)
Women treated with the drug saw a mean increase in time-to-progression of 3.4 months, the researchers found, which is similar to that of new targeted drugs such as trastuzumab or lapanitib. ❋ Unknown (2008)
In preclinical studies, ARRY-380 was superior in reducing tumor size when compared to selective HER2 inhibitors, such as trastuzumab, and was active when combined with other standard-of-care therapies. " ❋ Unknown (2009)
The drug is similar in concept to Roche Holding AG's trastuzumab-DM1, or T-DM1, being developed with ImmunoGen Inc., which has also developed a linking mechanism That drug attaches a cell-killing agent to breast-cancer blockbuster Herceptin, but it recently had a setback when the FDA rejected its accelerated approval application. ❋ Thomas Gryta (2010)
The drug is similar in concept to Roche Holding AG's trastuzumab-DM1, or T-DM1, being developed with ImmunoGen Inc. ❋ Thomas Gryta (2010)
Targeted therapy with trastuzumab (Herceptin) can help the 20 percent of breast-cancer patients who have a protein called human epidermal growth factor receptor 2 (HER-2). ❋ Post (2011)
Serrano said the findings suggest that elderly women with one or more heart risk factors who are being treated with trastuzumab should be referred to a cardiologist. ❋ Unknown (2011)